Abstract
Objective To determine the early electrocardiographic changes in a cohort of ambulatory cameroonian COVID-19 patients treated with hydroxychloroquine and Azithromycin.
Design Prospective study.
Setting Treatment centres of the city of Yaounde, Cameroon, from May 7th to 24th 2020.
Participants We enrolled 51 consecutive confirmed COVID-19 on RT-PCR who having mild forms of COVID-19 and treated by hydroxychloroquine 200mg twice daily during seven days plus Azithromycin 500 mg the first day and 250 mg the remaining 4 days as per national standard.
Main outcomes measures The primary end-point was the change in QTc interval between day 0 (D0), day 3 (D3) and day 7 (D7). Secondary endpoints were changes in all other cardiac electrical conductivity patterns and the occurrence of clinical arrhythmic events during the course of treatment.
Results The population (29 men and 22 women) was aged 39 ± 11 years (range 17 to 61 years). Mean Tisdale score was 3.35±0.48. No significant change from baseline (D0) of QTc was observed at D7 (429±27 ms at D0 versus 396±26 ms at D7; p=0.27). A reduction of heart rate was observed between the D0 and D7 (75±13 bpm versus 70±13 bpm, p = 0.02) with increased QRS duration between D0 and D7 (95±10 ms versus 102±17 ms, p = 0.004). No symptomatic arrhythmic events occurred during the treatment course.
Conclusions No life-threatening modifications of the QT interval was observed in non-severe COVID-19 patients treated ambulatory with hydroxychloroquine and azithromycin. Studies are needed in critical-ill and older patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the National Committee for Research Ethics in Human Health, Cameroon (Number 2020/05/1505/L/CNERSH/SP).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available under request with prior approval by the Nationa Ethics Committee and the Scientific Advisory Board of Public Health Emergencies of Cameroon
